Over 60 million invasive PAP smear tests are taken annually in the US alone.
GTHP's biophotonic scan is noninvasive, more accurate and produces immediate results.
"Guided Therapeutics, Inc. (GTHP) (GTHP), today announced that the LuViva® Advanced Cervical Scan, its non-invasive device used to detect cervical disease instantly at the point of care, has been selected as a finalist in the Hospital Devices and Therapeutic Products’ category of the 17th Annual Medical Device Excellence Awards (MDEA) competition. Selected products excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery. Winners will be announced at the 2014 MDEA Ceremony held Wednesday, June 11, 2014 in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York.
“We are extremely pleased to be chosen as a finalist for this prominent award,” said Gene Cartwright Chief Executive Officer of Guided Therapeutics. “Being recognized by the Medical Design and Diagnostic Industry (MD+DI) reinforces the exceptionality and innovation that is at the fundamental core of the technology behind LuViva as well as the benefits it provides to not only the patient but the healthcare system as well."